ABE1889

Anti-ZMYND11 Antibody

serum, from rabbit

• Synonym(s): Zinc finger MYND domain-containing protein 11
• UNSPSC Code: 12352203
• eCl@ss: 32160702
• NACRES: NA.41

Properties

• biological source: rabbit
• Quality Level: 100
• antibody form: serum
• antibody product type: primary antibodies
• clone: polyclonal
• species reactivity: human
• species reactivity (predicted by homology): mouse (based on 100% sequence homology)
• technique(s): ChIP: suitable (ChIP-seq); western blot: suitable
• NCBI accession no.: NP_001186070
• UniProt accession no.: Q8R5C8
• shipped in: dry ice
• target post-translational modification: unmodified
• Gene Information: mouse ... Zmynd11(66505)

Description

General description

Zinc finger MYND domain-containing protein 11 (UniProt Q8R5C8) is encoded by the Zmynd11 gene (Gene ID 66505) in murine species. ZMYND11/BS69 functions as a co-repressor of adenovirus E1A and cellular transcription factors including the c-Myb and ETS-2 oncoproteins. ZMYND11 contains several histone reader motifs, including a plant homeodomain (PHD), a bromodomain, and a PWWP domain. Lys36-trimethylated histone H3 (H3K36me3) is deposited onto the nucleosomes in the transcribed regions after RNA polymerase II elongation, and ZMYND11 is found to specifically recognize H3K36me3 and regulate RNA polymerase II elongation. Binding study showed that the combined PHD-bromo-PWWP (PBP) module mediates ZMYND11 recognition of H3K36me3 and PWWP domain alone displays little to no affinity toward H3K36me, H3K36me2, or unmethylated H3K36. ZMYND11 is a tumor suppressor that functions as an unconventional transcription co-repressor by modulating RNA polymerase II at the elongation stage. Low expression levels of ZMYND11 in breast cancer patients correlate with poor prognosis. Consistently, ZMYND11 overexpression suppresses cancer cell growth in vitro and tumor formation in mice in vivo.

Specificity

This antiserum detects two immunoreactive bands by Western blotting analysis of U2OS nuclear extract, ZMYND11 shRNA treatment specifically abolished the ~70 kDa band, but not the ~60 kDa band. The detection of the non-ZMYND11 band by Western blotting does not affect this antiserum′s performance in chromatin immunoprecipitation (ChIP) application. ZMYND11-knockdown by shRNA treatment prior to ChIP with this antiserum abolished the DNA fragments present in the immunoprecipitates from non-shRNA treated cells. In addition, ChIP profile obtained with this antiserum closely resembles that obtained using an anti-FLAG antbody and cells expressing FLAG-tagged ZMYND11.

Immunogen

Epitope: C-terminal region.

His-tagged recombinant mouse ZMYND11 C-terminal fragment.

Application

Detect ZMYND11 using this Anti-ZMYND11 Antibody validated for use in Western Blotting, Chromatin Immunoprecipitation (ChIP), ChIP-seq.

Research Category
Epigenetics & Nuclear Function

Research Sub Category
Chromatin Biology

Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected a downregulated ZMYND11 level in human osteosarcoma U2OS cell nuclear extracts following ZMYND11 shRNA treatment (Courtesy of Dr. Hong Wen, UT M.D. Anderson Cancer Center, TX).
Chromatin Immunoprecipitation Analysis: A representative lot detected ZMYND11 occupancy of c-Myc gene by ChIP using human osteosarcoma U2OS cell nuclear extracts. ZMYND11 shRNA treatment greatly reduced the c-Myc gene fragments in ChIP (Courtesy of Dr. Hong Wen, UT M.D. Anderson Cancer Center, TX).
Chromatin Immunoprecipitation (ChIP) Analysis: A representative lot detected ZMYND11 chromatin occupancy by ChIP using chromatin preparations from human osteosarcoma U2OS cells. Decreasing H3K36me3 level by SETD2 knockdown reduced ZMYND11 target genes association (Wen, H., et al. (2014). Nature. 508(7495):263-268).
ChIP-seq Analysis: A representative lot detected ZMYND11-targeted chromatin sites by a genome-wide ChIP-seq analysis using chromatin preparations from human osteosarcoma U2OS cells. The ZMYND11 occupied sites are highly enriched in introns and exons, but not promoters of targeted genes (Wen, H., et al. (2014). Nature. 508(7495):263-268).
Western Blotting Analysis: A representative lot detected exogenously expressed human BS69 protein in yeast and QT-6 quail fibroblasts (Ladendorff, N.E., et al. (2001). Oncogene. 20(1):125-132).

Quality

Evaluated by Western Blotting in U2OS nuclear extract.

Western Blotting Analysis: A 1:500 dilution of this antibody detected ZMYND11 in 20 µg of U2OS nuclear extract.

Target description

~70 kDa observed. 70.96 kDa (isoform 1), 64.43 kDa (isoform 2), 66.59 kDa (isoform 3), 60.05 kDa (isoform 4), 60.87 kDa (isoform 5), and 66.52 kDa (isoform 6) calculated.

Physical form

Rabbit polyclonal serum with 0.05% sodium azide.

Unpurified

Storage and Stability

Stable for 1 year at -20°C from date of receipt.
Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.

Other Notes

Concentration: Please refer to lot specific datasheet.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Safety Information

• Storage Class Code: 12 - Non Combustible Liquids
• WGK: WGK 1
• Flash Point(F): Not applicable
• Flash Point(C): Not applicable